FATP1 inhibition appears to be a viable treatment method since it raised FATP1/SLC27A1 expression in human triple-negative breast cancer, which was associated with a significant reduction in overall survival [27]. The gene discussed is SLC27A1; the disease is triple-negative breast carcinoma.